NEW YORK (Reuters Health)—Guselkumab may be effective in patients who have psoriatic arthritis (PsA) with axial symptoms, a post-hoc analysis of data from two randomized controlled trials suggests.1 “Because PsA is a heterogeneous disease that manifests as various symptoms, treatment choices should involve consideration of all relevant domains of disease for each individual patient,” researchers…
Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed GCA
NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…
Health Canada Approves Upadacitinib to Treat Adults with PsA
Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.
Guselkumab Promising to Slow Joint Damage in Patients with Psoriatic Arthritis
In an efficacy and safety study of guselkumab, patients with active psoriatic arthritis taking guselkumab showed continued skin clearance and joint symptom relief, as well as statistically significant inhibition of joint damage, after two years.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
Tofacitinib Promising for COVID-19 Pneumonia
(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…
Higher Risk of Adverse Events When Biologic Infusions Are Done at Home
(Reuters Health)—Patients who receive biologic infusions at home may have a higher risk of adverse events than those who receive the infusions at a health care facility, a new study suggests.1 Researchers examined administrative claims data on 57,220 adults who received a total of 752,150 biologic infusions for immune-mediated disease between 2007 and 2017. The…
Add-On Voclosporin Improves Outcomes in Lupus Nephritis
NEW YORK (Reuters Health)—Voclosporin (Lupkynis) in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study. “Lupus nephritis can be a devastating condition if not diagnosed and managed early. These data establish voclosporin as an…
Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar
Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.
The Race Is On: Clinical Trials Begin for Agents Biosimilar to Denosumab
As the U.S. and other patents for branded denosumab products get closer to expiring, drug manufacturers are initiating clinical trials for more affordable, biosimilar versions of the treatment.
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 121
- Next Page »